TICKERNERD
Menu
OGENOGENHealthcare · Biotechnology

OGEN Stock Forecast: Oragenics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.48
−8.33% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 19 Sept 2026 — in the weakest quartile.

Market cap
$2.2M
Ticker Nerd rank
10 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$2.3M
Net income−$2.2M
Free cash flow−$2.2M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.7%
1M
−13.3%
YTD
−38.9%
1Y
−60.6%
From 52W high
−66.4%
From 52W low
0.0%
$0.48
$1.42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Oragenics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
10 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Issuance
57
Volatility
32
Growth
27
Revisions
25
Accruals
18
Quality
16
Momentum
10
Value
5

Size (99): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.40$0.60$0.80$1.00$1.20$1.40Oct 25Jan 26Apr 26Jul 26OGEN

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 June 2021Goldman SachsInitiatesNeutral—
16 Apr 2020H.C. WainwrightDowngradeNeutral—
16 Apr 2020HC Wainwright & Co.DowngradeNeutral—
15 Nov 2019UBSMaintainsNeutral—
26 Apr 2019H.C. WainwrightInitiatesBuy—
26 Apr 2019HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Oragenics, Inc. returned −60.6% against +16.3% for the S&P 500, dividends included.

OGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26OGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Oragenics, Inc. (OGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.5×

Cheaper than 71% of US stocks

Price / sales
—
Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1307.1%

Higher than 1% of US stocks

Return on assets
−171.5%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Oragenics, Inc. (OGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oragenics, Inc. has a market value of $2.2M and an enterprise value of −$1.7M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$9.8M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$9.3M.

  • Shares outstanding: 4.5M.

  • Trailing P/E: 0.5×; forward P/E: −0.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Oragenics, Inc. employs 3 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

OGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OGENOragenics, Inc.$2.2M
10
CRISCuris, Inc.$2.1M
36
PPCBPropanc Biopharma, Inc.$2.1M
40
ARTLArtelo Biosciences, Inc.$2.2M
15
VBIOValion Bio, Inc.$1.9M
2
DCOYDecoy Therapeutics, Inc.$1.8M
13
MTNBMatinas BioPharma Holdings, Inc.$2.4M
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Oragenics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OGEN news & analysis

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

GlobeNewsWire · 16 Sept 2026positive

Oragenics Chief Medical Officer James P. Kelly, MD, is scheduled to present at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. His presentation will cover the development and clinical translation of the ONP-002 intranasal delivery platform for concussion treatment, including the Phase IIa trial design and expected path to U.S. clinical development.

Why it matters — The presentation provides Oragenics with a prominent platform to highlight the clinical translation of its ONP-002 intranasal delivery platform to leading pharmaceutical scientists, device developers, and regulators in the nasal drug delivery field.

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

GlobeNewsWire · 28 Aug 2026positive

Oragenics, Inc. provided an update on its Phase IIa clinical trial for its intranasal brain-targeted therapeutics, along with its U.S. regulatory pathway and NYSE American continued listing status. The company described the progress as continued clinical advancement in its latest announcement.

Why it matters — OGEN watchers would follow this update because it covers key milestones on the company's clinical trial progress, regulatory path, and ability to maintain its NYSE American listing.

FAQ

Frequently asked questions about OGEN stock

Is OGEN stock a buy right now?

Of the 1 analysts covering Oragenics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oragenics, Inc. 10 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OGEN?

As at 19 Sept 2026, Oragenics, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the OGEN stock forecast for 2030?

No analyst covering Oragenics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGEN are extrapolating price history, which says nothing about the business.

How has OGEN stock performed over the past year?

Oragenics, Inc. returned -60.6% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oragenics, Inc. do?

Oragenics Inc. is a clinical-stage biopharmaceutical company focused on intranasal drug delivery for neurological conditions and infectious diseases.

What is the latest news on OGEN?

The most recent item we track (GlobeNewsWire, 16 Sept 2026): "Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum". Oragenics Chief Medical Officer James P. Kelly, MD, is scheduled to present at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. His presentation will cover the development and clinical translation of the ONP-002 intranasal delivery platform for concussion treatment, including the Phase IIa trial design and expected path to U.S. clinical development.

Company

About Oragenics, Inc.

Oragenics Inc. is a clinical-stage biopharmaceutical company focused on intranasal drug delivery for neurological conditions and infectious diseases. The company’s current work centers on developing ONP-002, a lead neurosteroid candidate being studied for mild traumatic brain injury, including concussion. Oragenics uses proprietary nasal delivery technology designed to transport therapies directly to the brain, supporting targeted, non-invasive treatment approaches. Its platform also includes research in powdered drug formulations and other nasally delivered pharmaceutical products aimed at addressing unmet medical needs in neurology. Based in Florida, Oragenics positions itself within the biotechnology sector as a developer of specialized therapies for brain-related disorders and select infectious disease applications.

CEO Ms. Janet Huffman · 3 employees · United States · https://www.oragenics.com